Lenalidomide Capsule
Product Images NDC 59651-342

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 59651-342). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Lenalidomide Str)

Chemical structure of lenalidomide depicted as a molecular diagram, showing rings and functional groups consistent with the compound's chemical formula.*

FDA Label Image

Lenalidomide-fiugure-1 (Lenalidomide Fig1)

A survival probability plot showing progression-free survival in months for three treatment groups: Rd Continuous, Rd18, and MPT. The chart displays survival probability percentages on the y-axis and progression-free survival duration on the x-axis, with data points and confidence intervals. Below the graph is a table listing the number of subjects at risk over time for each group, and summary statistics for progression-free survival events are provided at the bottom.*

FDA Label Image

Lenalidomide-fiugure-2 (Lenalidomide Fig2)

A survival probability Kaplan-Meier curve chart showing overall survival rates over 72 months for three treatment groups: Rd Continuous, Rd18, and MPT. The chart includes a survival probability (%) y-axis and overall survival (months) x-axis. A table below displays the number of subjects at risk for each group at different time points.*

FDA Label Image

Lenalidomide-fiugure-3 (Lenalidomide Fig3)

A Kaplan-Meier curve chart showing the proportion of subjects over time to progression in months. Two groups are compared: Lenalidomide/Dex and Placebo/Dex. The graph indicates a higher proportion of subjects without progression over time in the Lenalidomide/Dex group, with a hazard ratio (HR) of 0.285 (95% CI: 0.210 to 0.386) and a Log Rank p-value of less than 0.001.*

FDA Label Image

Lenalidomide-fiugure-4 (Lenalidomide Fig4)

Kaplan-Meier plot showing proportion of subjects over time to progression in months. The graph compares two groups: Lenalidomide/Dex and Placebo/Dex, with the Lenalidomide/Dex group showing a higher proportion of subjects remaining without progression. Statistical results include a hazard ratio (HR) of 0.324 with 95% confidence interval (0.240 to 0.438) and a log-rank p-value less than 0.001.*

FDA Label Image

Lenalidomide-fiugure-5 (Lenalidomide Fig5)

Lenalidomide Capsules 2.5 mg oral capsules label showing a 100-capsule package. The label includes a warning about potential human birth defects, storage instructions, distributor information for Aurobindo Pharma USA, Inc., and a barcode on the right side. The product is made in India by Aurobindo Pharma Limited.*

FDA Label Image

Lenalidomide-fiugure-6 (Lenalidomide Fig6)

Packaging label for Lenalidomide Capsules 2.5 mg oral dosage form by Aurobindo Pharma Limited. The unit-dose package contains 7 capsules (1 x 7). Label includes storage instructions, distributor info (Aurobindo Pharma USA, Inc.), and a warning about potential for human birth defects. NDC 59651-342-07 is visible along with barcodes and the directive for pharmacists to dispense the Medication Guide.*

FDA Label Image

Lenlidomide-figure-7 (Lenalidomide Fig7)

Label for Lenalidomide Capsules 5 mg by Aurobindo Pharma Limited, containing 100 capsules. The label includes a warning about potential human birth defects, storage instructions, and distributor information for Aurobindo Pharma USA, Inc., along with a barcode and a note to dispense the medication guide to patients.*

FDA Label Image

Lenlidomide-figure-8 (Lenalidomide Fig8)

Packaging label for Lenalidomide Capsules 5 mg, an oral human prescription drug by Aurobindo Pharma Limited. The label indicates 7 unit-dose capsules per package and includes warnings about potential birth defects and instructions for pharmacists to dispense a medication guide. The label also displays storage instructions and distributor details for Aurobindo Pharma USA, Inc.*

FDA Label Image

Lenlidomide-figure-9 (Lenalidomide Fig9)

Label for Lenalidomide Capsules 10 mg, an oral capsule prescription drug. The label states a package size of 100 capsules and includes a warning about potential human birth defects. Distributed by Aurobindo Pharma USA, Inc., with manufacturing in India. Storage instructions specify 20° to 25°C. The label features the Aurobindo logo and provides a website for medication guides.*

FDA Label Image

Lenlidomide-figure-10 (Lenalidomide Fig10)

Packaging label for Lenalidomide Capsules, 10 mg, oral dosage form by Aurobindo Pharma USA, Inc. The label states the product contains 7 unit-dose capsules (1 x 7). It includes warnings about potential human birth defects and storage instructions at 20-25°C. The label features the NDC 59651-344-07 and advises pharmacists to dispense the Medication Guide separately to each patient.*

FDA Label Image

Lenalidomide-figure-11 (Lenalidomide Fig11)

Label for Lenalidomide Capsules 15 mg by Aurobindo Pharma Limited. The label indicates each capsule contains 15 mg Lenalidomide and comes in a package of 100 capsules. It includes a warning about potential human birth defects and prescribing information references. Distributed by Aurobindo Pharma USA, Inc., made in India. Storage instructions specify 20 to 25°C (68 to 77°F).*

FDA Label Image

Lenlidomide-figure-12 (Lenalidomide Fig12)

Packaging label for Lenalidomide Capsules 15 mg oral capsules by Aurobindo Pharma USA, Inc. The carton contains 7 unit-dose capsules (1 x 7). The label includes warning about potential for human birth defects and advises pharmacists to dispense a medication guide. Storage instructions and distributor information (Aurobindo Pharma USA, East Windsor, NJ) are also printed with barcodes on the sides.*

FDA Label Image

Lenlidomide-figure-13 (Lenalidomide Fig13)

Lenalidomide Capsules 20 mg oral capsules label shows a 100-capsule package by Aurobindo Pharma Limited. The label includes a warning about potential human birth defects, storage instructions at 20-25°C, and distributor information for Aurobindo Pharma USA, Inc. It also directs pharmacists to dispense the Medication Guide separately.*

FDA Label Image

Lenalidomide-figure-14 (Lenalidomide Fig14)

Packaging label for Lenalidomide Capsules 20 mg oral dosage form by Aurobindo Pharma Limited. The unit-dose package contains 7 capsules (1 x 7). The label includes a warning about the potential for human birth defects and storage instructions to keep at 20° to 25°C. Distributed by Aurobindo Pharma USA, Inc., made in India.*

FDA Label Image

Lenlidomide-figure-15 (Lenalidomide Fig15)

Label for Lenalidomide Capsules 25 mg oral dosage form by Aurobindo Pharma Limited. The label states a 100-capsule count with a warning about potential human birth defects. It includes storage instructions, distributor information (Aurobindo Pharma USA, Inc.), and a website link for medication guides. The label features the NDC number 59651-347-01.*

FDA Label Image

Lenlidomide-figure-16 (Lenalidomide Fig16)

Packaging label for Lenalidomide Capsules 25 mg oral capsules by Aurobindo Pharma USA, Inc. The unit-dose box contains 7 capsules (1 x 7) and prominently displays warnings about potential human birth defects. Storage instructions specify temperatures between 20° to 25°C. The label features the Aurobindo logo and includes multiple barcodes and NDC number 59651-347-07.*

FDA Label Image

Lenalidomide-figure-17 (Lenalidomide Fig17)

Label for Lenalidomide Capsules 25 mg oral capsules by Aurobindo Pharma Limited. The label states 100 capsules per container and includes storage instructions (20° to 25°C), a warning of potential human birth defects, and the distributor address: Aurobindo Pharma USA, Inc. Made in India. The NDC code is 59651-347-01.*

FDA Label Image

Lenalidomide-figure-18 (Lenalidomide Fig18)

Packaging label for Lenalidomide Capsules 25 mg oral dosage form by Aurobindo Pharma USA, Inc. The label shows the 7 (1 x 7) unit-dose capsule package, with warnings about potential human birth defects and instructions for pharmacists to dispense the medication guide. It includes storage instructions at 20° to 25°C and details that the package is not child resistant. The label displays the NDC 59651-347-07 and is marked Rx only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.